Targeting control and elimination of NIDs through clinical trials – 2017
Neglected Infectious Diseases (NIDs, also known as Neglected Tropical Diseases) are a diverse group of diseases that affect an estimated 1.2 billion people worldwide. Global investment into research and development of new products for NIDs is limited and there is an urgent need to develop new or improved products and to optimise the use of existing products in order to achieve disease elimination. The objective of this call for proposals is to provide funding for clinical trials to accelerate the development of new or improved therapeutics for NIDs in sub-Saharan Africa.
Call identifier: RIA2017NCT
See the corresponding call for proposals
HAT-r-ACC
Towards an arsenic-free oral treatment for human African trypanosomiasis due to Tb rhodesiense as a tool for disease elimination
Drugs for Neglected Diseases initiative (DNDi), Switzerland with partners from France, Malawi, Portugal, Switzerland, and Uganda
Project Coordinator: Dr Olaf Valverde Mordt, DNDi, Switzerland
Starting date: 1 September 2018
Duration: 60 months
Grant amount: EUR 3,769,846
Grant agreement: RIA2017NCT-1846
Project website
MoxiMultiDoseMod
Moxidectin for accelerating onchocerciasis elimination: a paediatric dose-finding study, two phase IIIb trials comparing efficacy and safety of single or annual and biannual moxidectin or ivermectin treatment and mathematical modelling of moxidectin- and ivermectin-based elimination strategies to support country policy decisions
Luxembourg Institute of Health (LIH), Strassen, Luxembourg with partners from Belgium, the Democratic Republic of the Congo, Ghana, the Netherlands, and the United Kingdom
Project Coordinator: Dr Michel Vaillant, LIH, Luxembourg
Starting date: 1 August 2019
Duration: 60 months
Grant amount: EUR 4,614, 319
Grant agreement: RIA2017NCT-1843
Project website
STOP
Towards the interruption of transmission of soil-transmitted helminths: Clinical research development of a fixed-dose co-formulation of ivermectin and albendazole
Fundación Privada Instituto de Salud Global (ISGlobal), Barcelona, Spain with partners from Ethiopia, Kenya, Mozambique, Netherlands, Spain, and the United Kingdom.
Project Coordinator: Dr José Muñoz Gutiérrez, ISGlobal, Spain
Starting date: 1 October 2018
Duration: 60 months
Grant amount: EUR 4,899,488
Grant agreement: RIA2017NCT-1845
Project website
STOP-2
Towards the interruption of transmission of soil-transmitted helminths: Safety of a fixed-dose co-formulation of ivermectin and albendazole *
Fundación Privada Instituto de Salud Global (ISGlobal), Barcelona, Spain with partners from Kenya, the Netherlands, Spain, and the United Kingdom.
Project Coordinator: Dr José Muñoz Gutiérrez, ISGlobal, Spain
Starting date: 1 October 2020
Duration: 12 months
Grant amount: EUR 1,665,298
Grant agreement: PSIA2020-3072 – STOP-2
* This project is funded by the United Kingdom as an independent contribution to the EDCTP2 programme, a so-called Participating States’ Initiated Activity. The study follows up on the EDCTP-funded STOP study.